Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29083323 | 1.00 | TLR2 (0.43) | TLR2KMT2ACASP3MDM2PTPN1 | |
| SCHEMBL12356377 | 0.88 | TLR2 (0.54) | TLR2KMT2A | |
| SCHEMBL19447831 | 0.88 | TLR2 (0.46) | TLR2KMT2AMDM2PTPN1 | |
| SCHEMBL26232059 | 0.87 | KMT2A (0.55) | TLR2KMT2ACASP3PTPN1 | |
| SCHEMBL29083319 | 0.87 | KMT2A (0.55) | TLR2KMT2ACASP3PTPN1 | |
| SCHEMBL29799306 | 0.87 | KMT2A (0.55) | TLR2KMT2ACASP3PTPN1 | |
| SCHEMBL23927994 | 0.87 | TLR2 (0.49) | TLR2KMT2ACASP3MDM2 | |
| SCHEMBL23927996 | 0.87 | TLR2 (0.49) | TLR2KMT2ACASP3MDM2 | |
| SCHEMBL29358858 | 0.86 | TLR2 (0.46) | TLR2MDM2PTPN1 | |
| SCHEMBL29083312 | 0.86 | TLR2 (0.42) | TLR2KMT2ACASP3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279662-A | Branched linkers for antibody-drug conjugates and methods of use thereof | R.P.谢勒技术有限责任公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116847844-A | Camptothecine antibody-drug conjugates and methods of use thereof | R.P.谢勒技术有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | TLR2 4391/4885KMT2A 1187/4885CASP3 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.